longitudinal studies. Changes have been proposed to the federal policy for human subjects research protections, but current regulations and administrative policies-developed under a protectionist paradigm in response to scandalous research practices with confined populations-dramatically limit research involving prisoners. Our review provides rationale for the development of Initiative policies that anticipate recruitment and retention obstacles that might frustrate inclusivity and exacerbate health disparities. Furthermore, we question the effective ban on biomedical and behavioral research involving prisoners and advocate for regulatory reforms that restore participatory research rights of prisoners. Disparities in health and justice are intertwined, and without regulatory reforms to facilitate participatory research rights of prisoners and careful planning of viable and responsible recruitment, engagement, and retention strategies, Initiative could miss discovery opportunities, exacerbate health disparities, and increase levels of distrust in science.
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The National Institutes of Health (NIH) has launched the Precision Medicine Initiative R (PMI), an ambitious 10-year longitudinal project planning to involve the collection and study of biospecimens, electronic health records, surveys, and extensive lifestyle and behavioral data via mobile apps and sensors and a target cohort of one million individuals that is reflective of the nation's diversity. 1 The PMI website boasts, 'Anyone in the United States will be able to voluntarily enroll', and NIH Director Dr. Francis Collins has indicated the PMI wants to include participants 'from all walks of life'.
2, 3 The PMI Working Group underscored the importance of an inclusive cohort in its final report; noted exclusions of any kind-even exclusion of groups considered to be vulnerable populations-would undermine the project's scientific integrity and potential to improve healthcare for all; and made two specific recommendations relevant to the present discussion, as shown in Table 1 . 4 The NIH has acknowledged that creating such an inclusive cohort will be challenging and necessitate modernization of current regulatory frameworks in order to accommodate and provide appropriate oversight for participatory research. 5 discussion about the challenges to inclusivity or potential ways in which those challenges can be overcome, which is concerning given recruitment for the PMI All of Us
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Research Program 9 is imminent. Here, we examine one specific challenge for the PMI: the inclusion of individuals who are or become incarcerated during the Initiative. We use this study as an example to demonstrate the importance of comprehensive regulatory reforms for research that enable the participation of prisoners.
THE SOCIAL CONTE XT IN WHICH PMI WILL BE IMPLEMENTED
The PMI will not be implemented in an ideal world (where all individuals have equal access to healthcare and equal opportunity to participate in biomedical research and to share in its benefits) but within the context of societal realities of mass incarcerations and a criminal justice system that disproportionately affects minorities. The USA has one of the largest prison populations and highest incarceration rates in the world. According to the Bureau of Justice Statistics, there are approximately 6.85 million adults (1 in 36, or 2.8% of the US population) under correctional supervision, with 1.5 million held in state and federal correctional facilities, 744 thousand held in local jails, and 4.7 million on probation or parole. The incarceration rate in 2014 was 900 per 100,000 US adults. 10, 11, 12 The lifetime likelihood of imprisonment of US residents born in 2001 for men was 1 in 9 and women was 1 in 56.
13 Incarceration rates vary greatly by racial and ethnic background (as shown in Table 2 ), and these disparities in incarceration rates vary among states. In Pennsylvania, eg African Americans make up 10.6% of the population but 48.7% of the prison population, and the racial disparity in the incarceration rate shows nearly nine African Americans to one European American. Both the absolute numbers of individuals in this vulnerable population (ie prisoners) whom the PMI has expressed an interest in including and these disparities in incarceration rates are relevant to the PMI's viable retention strategies. Incarceration rates that disproportionately affect racial and ethnic minorities, who are already underrepresented in biomedical research, are a serious concern for longitudinal, participatory studies. 16 In addition to over-sampling strategies for recruitment of under-represented minorities into All of Us, PMI must prepare for the collateral damage that mass incarcerations and racial disparities in criminal justice cause-eg biased interruptions and drop-outs of not only the individual who becomes incarcerated but also family members and friends whose interest and available time to commit to the study might wane. High incarceration rates suggest programmatic challenges for the PMI, including the need to track participants to identify when they become prisoners in any jurisdiction and managing the potential disruptions (eg involuntary suspension of participation or disengagement).
Moreover, inclusion of prisoners is particularly important for the study of conditions and diseases that disproportionately affect prisoners at higher rates than the general non-prisoner population. Prisoners are reported to suffer higher rates of infectious disease, chronic conditions, and mental health conditions 17 (including, for example, hepatitis C, HIV/AIDS, tuberculosis, oral health problems, mental health problems, substance use disorders, 18 diabetes, heart disease, and cancer 19 ). Yet there are few national health data sets that include any information relevant for examining associations between incarceration and health. 20 The World Health Organization has acknowledged, 'public health can no longer afford to ignore prison health', 21 and others have started to consider prisoner health as 'integral' to the public health system. 22 As Wakai et al. (2009) have noted, it is impossible 'to provide effective evidence-based care for inmates' unless research is conducted to understand 'their particular circumstances, health histories, and environmental exposures'. 23 Nevertheless, there are scarce data involving prisoners or their perspectives on research.
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A BRIEF HISTORY OF RESE ARCH INVOLVING PRISONER S
The history of prisoners' involvement in biomedical research that led to proscriptive regulations in 1978 to protect prisoners from exploitation (but were, we believe, an over-correction and have functioned as an effective ban on prisoner participation in research) has been well documented elsewhere. 25 It does, however, warrant a special note that research involving prisoners during its peak in the 1960s and 1970s is appropriately described as research conducted on prisoners as subjects (as opposed to a more equitable process of research conducted with prisoner-participants as partners). Prisoners were injected, infected, and exposed in all sorts of bizarre and horrific studies, including experiments for understanding cholera, pellagra, malaria, gonorrhea, herpes, influenza, cosmetic safety, testicular radiation, and chemical warfare agents.
26 Stated bluntly, the research involved experimentation that non-prisoners would refuse. For example, by 1972 more than 90% of investigational drug toxicity testing was conducted on prisoners.
27 Confinement and pressures of prison cultures (including power dynamics, susceptibility to monetary inducements, and boredom) seemingly provided an 'unlimited supply of available, trackable, and willing subjects'. 28 Prisons became known as a special environment in which voluntary informed consent is inherently problematic because the possibility of coercion is high and in which the dangers of exploitation are escalated compared to those risks in society.
CURRENT BARRIER S TO RESE ARCH INVOLVING PRISONER S
Federal regulations for research are set generally in subpart A of 45 C.F.R. part 46 (otherwise known as the 'Common Rule'). These regulations set forth the federal policy to ensure that federally funded research involving humans is conducted ethically and does not unjustifiably or unreasonably place humans in danger. The Common Rule requires research protocols to be reviewed by institutional review boards (IRBs) to evaluate the benefits and risks before the research begins, provide oversight during the study, and ensure research is conducted pursuant to voluntary, informed consent by each participant. Research involving prisoners, classified as a 'vulnerable population', must also comply with specific regulations of subpart C of 45 C.F.R. part 46. For regulatory purposes, 'prisoner' is defined as 'any individual involuntarily confined or detained in a penal institution' and includes those detained after sentencing as well as those awaiting arraignment, trial, or sentencing. 29 Regulatory exemptions are not available for research involving prisoners. Moreover, the extra regulations of subpart C apply not only when prisoners are the focus of the study's recruitment but also when participants incidentally become prisoners during the study. 30 In addition to subpart C's provisions regarding composition of the IRBs and additional findings required before IRBs approve research, subpart C, 45 C.F.R. §46.306(a), permits only that research fitting one of four categories: (1) studies of the criminal behavior and incarceration (such as causes, effects, and processes); (2) studies of prisons as institutions; (3) studies of conditions affecting prisoners as a class, subject to conditions; and (4) studies of practices that benefit and likely improve the individual's health or well-being, subject to conditions. Unless one of the aforementioned categories is applicable, 'biomedical or behavioral research...shall not involve prisoners as subjects'. Subpart C also requires that researchers obtain certification for their projects by the 26 
Secretary of the Department of Health and Human Services (DHHS), typically done through the Office of Human Research Protections (OHRP).
31 If a participant becomes incarcerated during a study not originally approved as research involving prisoners, the individual's participation is to be immediately suspended; no interactions, interventions, or exchanges of identifiable private information are to occur; researchers are to notify the IRB; and the IRB must re-review the protocol to ensure the requirements of subpart C are met before participation may resume.
32 A waiver to the subpart C provisions is available for epidemiological research that has the sole purpose either to describe a disease's prevalence or incidence or to study potential risk factors for a disease but only if the research involves no more than minimal risk, involves only an inconvenience to the prisoners, and is not particularly focused on prisoners.
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There are also administrative barriers to research involving prisoners. Prisoners are not under uniform supervision but are held in federal, state, local, and sometimes private facilities, and proposed research must also comply with policies of the appropriate authority. The Federal Bureau of Prisons (BOP) Program Statement 1070.07 is clear: 'The project must not involve medical experimentation, cosmetic research, or pharmaceutical testing'. 34 As an example of state policy, the PA Department of Corrections policy similarly states, 'The use or employment of an inmate as a subject in any medical, pharmaceutical, or cosmetic experiments or testing is prohibited', and the authority allows only research that increases knowledge of correction practices, management, or facilities. 35 Two of the largest private companies in the US prison system, Corrections Corporation of America and GEO Group, have no publicly available online policy statements regarding research.
REFOR MS SUGGESTED, PRISONER S IGNORED
In the 1970s when the regulations to curtail biomedical research involving prisoners were being contemplated, some prisoners complained of being excluded from research opportunities. 36 Calls to reconsider the bans on research involving prisoners intensified in the 1980s in connection specifically with the HIV/AIDS epidemic and the need for clinical trials. 37 In 2007, the Institute of Medicine (IOM) issued an extensive report, 'Ethical Considerations for Research Involving Prisoners', in which it examined past and present research involving prisoners and applicable regulations. 39 The IOM made five major recommendations:
(1) that the definition of prisoner be expanded to include incarcerations as well as other situations when liberty is constrained by correctional authorities, such as probation or parole; (2) that the rules apply uniformly regardless of funding source or type of correctional facility and the creation of a national public database of research involving prisoners; (3) that the category-based approach be replaced by a risk-based approach, in which direct benefits for each prisoner-participant outweigh the risks; (4) that the ethical framework be updated to promote 'collaborative responsibility'; and (5) enhance the systematic oversight for research involving prisoners, including more proactive monitoring by IRBs.
The IOM recognized that a realignment of the research regulatory framework is necessary to ensure that prisoners share in access to research, have a partnership role in that research, and are adequately protected by uniform rules. Nonetheless, the IOM reiterated that biomedical research must remain restricted when involving prisoners, recommending that it be permissible only when (1) the proposed research on a new prevention or treatment option has some evidence of safety and efficacy or (2) the ratio of prisoners to non-prisoners involved does not exceed 50%. Not until 2011 was the first major action taken to reform research regulations when the DHHS published an advanced notice of proposed rulemaking (ANPRM). 40 The ANPRM focused recalibrating oversight within a revised, risk-based framework. Despite the IOM's thorough analysis and recommendations, the ANPRM did not propose any revisions specific to subpart C, acknowledge the IOM's report, or otherwise discuss research involving prisoners. Rather, the ANPRM was explicitly focused narrowly on the Common Rule itself and drafters noted that the proposed changes could affect the subparts in ways that would require their subsequent harmonization. 41 years later, when DHHS issued a Notice of Public Rulemaking (NPRM) in 2015, it again expressly declined the opportunity to reform subpart C. 42 Nevertheless, three of the 88 questions posed for public comment (Questions 25, 57, and 58 shown in Table 3 ) inquired whether the proposed exclusions (at proposed §-.101(b)(2) and (3)) and exemptions (at proposed §-.104) should apply if not to all research involving prisoners then at least to those research projects in which the targeted population is predominantly non-prisoners. While the stated intent of this potential change is to relax constraints on prisoners' involvement in non-research activities or 'low risk' research activities, the actual language of the proposed regulatory text is contradictory and convoluted. Moreover, if research is planned with an equitable design (ie if researchers and participants are both anticipated to have access to individual data and results from the study) as PMI has been publicized, exemptions proposed at §-104(f) are not available.
The ANPRM and NPRM both sparked extensive public commenting, with more than 1050 public comments on the ANPRM and more than 2100 comments on the NPRM; however, a review and content analysis of these comments, as highlighted in Tables 4 and 5 , revealed scant coverage of how research involving prisoners might be affected. In 2002 when the epidemiological research waiver was first proposed, that action drew little attention or opposition (ie only 14 comments were submitted, 12 of which were supportive of the policy change). The NPRM has been severely criticized, calling into question the legitimacy of any regulations that might, on its basis, be issued without opportunity for the public to review a full detailed proposal and contribute to its refinement. A focused critique by Guerrnie, McGuire, and Majumder demonstrates how the NPRM 'will potentially impede' not only the PMI but also other efforts Unknown N = 1 N= 19
Framing of Comments
Neither N = 24 N = 35
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Revisions to Subpart C governing involving prisoners in research N = 5 N= 5
Fewer restrictions on prisoner involvement in research N = 6 N= 20
More restrictions on prisoner involvement in research N = 4 N= 3
to build a medical information commons. 43 In June 2016, the National Academies of Science, Engineering, and Medicine emphatically rejected the proposed reforms, called for the NPRM's withdrawal, and advocated for a comprehensive, robust review of the regulations to be performed by a new national commission dedicated to the task. 44 If a piecemeal approach to regulatory reform moves forward and focuses only on the Common Rule, the research and healthcare gap between prisoners and non-prisoners will only widen.
RESE ARCH PARTICIPATION DENIED: 'IT'S FOR THEIR OWN
PROTECTION' As Carol Levine described in 1988, 'the basic approach to the ethical conduct of research...was born in scandal and reared in protectionism'. 45 The restrictive federal more equitable one-participation. Responsible research involving prisoners continues to require diligence and oversight to ensure voluntariness and overcome the potential for consent to be an act of acquiescence or compliance with a perceived requirement or preference by prison officials who control the prisoners' liberties and privileges, compromised by an individual's inability to understand the scope of the research and risks, and tainted by research incentives that seem minor to non-confined populations but amount undue influences within the prison setting (eg such as an opportunity to escape boredom or crowded spaces or access to snacks). While policies to shield prisoners from exploitation remain important, it is time to recognize existing regulations have become handcuffs restricting prisoners' ability to participate. Existing bioethics literature lacks careful evaluation of prisoners' participation in research from a participatory perspective, 47 although there have been a few advocates calling for a relaxation of prisoner research restrictions. 48 Recent research efforts, including PMI, mark a noticeable shift in the scientific enterprise that values individuals as meaningful research partners (ie not passive subjects or mere data sources but active collaborators in the design, conduct, and publication of research). Regulatory reforms must be reconsidered such that these developing norms can be adequately taken into account. Researchers must be encouraged to think critically and inclusively in research design so that individuals from vulnerable populations are not unnecessarily excluded simply because of their vulnerable status, which could only widen the divide between those privileged to enjoy in the benefits of science.
Participating in science and enjoying benefits from the advancement of science are human rights. 49 Some have even described participation in research as a duty. 50 At a minimum, contributions to science are a form of community service that should be acknowledged and facilitated. Restoring participatory research rights for prisoners could enable the development of innovative accelerated rehabilitative disposition programs that inspire STEM careers. Furthermore, it could enable prisoners, despite physical separation from society, to have positive, shared experiences with family and friends who participate in research together and additionally function as one way to mend, preserve, or strengthen their connections with society. Finally, we caution that as precision medicine and integration of research in healthcare become standard practice, continued 'protection' of prisoners from research activities might constitute a deliberate indifference to their human and constitutionally protected right to adequate healthcare, a point which we elaborate below. Innovative, responsible approaches to destigmatize research involving prisoners and enable participatory research for conditions and health outcomes of particular relevance for that vulnerable population should be encouraged with appropriate support and oversight. 47 See Supplemental Materials. 48 
IMPROVING PRISON HE ALTHCARE THROUGH THE INTEGRATION
OF RESE ARCH It is perhaps ironic that prisoners comprise the one segment of American society that has been recognized as having a constitutional right to adequate healthcare 51 but are simultaneously excluded from the activities intended to improve healthcare outcomes. 52 Healthcare in the correctional setting must align with 'contemporary standards of decency' to avoid 'unnecessary suffering'. 53 Accordingly, prisoner medicine must meet baseline requirements set by the US Constitution, federal laws, and standard of care, although practically that bar is set very low. 54 In some circumstances, inadequate medical services in prisons can violate the prohibition against cruel and unusual punishment. The test as to whether prison officials can be held accountable for providing inadequate medical services has been a subjective one of 'deliberate indifference', 55 ie whether there was knowledge and a disregard of a serious medical need. 56 Courts have not always viewed this prisoner right to healthcare through this lens of cruel and unusual punishment, however. As other scholars have observed, 57 prior to the Estelle v Gamble decision by the Supreme Court, at least one court understood the obligation to provide healthcare to prisoners as arising precisely from the decision to remove the individuals from the societal context in which those individuals are in a position to help themselves. 58 From this perspective, incarceration is a juridic disability to which the government has a responsibility to address. 59 This view is accentuated as prisoner healthcare programs, if federally operated or assisted, are also subject 60 to Title II of the Americans with Disabilities Act (ADA) 61 and Section 504 of the Rehabilitation Act of 1973.
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A recent legal development adds another layer of complexity and further support for the argument that modernizing the federal policy for research participant protections should not overlook prisoner participatory rights. An overarching goal of the Patient Protection and Affordable Care Act (or ACA) 63 is to eliminate health disparities, 64 and Section 1557 of ACA prohibits discrimination in health programs and activities on the basis of protected class status (which includes disability as well as race, color, national origin, sex, age, and English proficiency). The Final Rule on Section 1557, which took effect on July 18, 2016, is intended to apply to biomedical research 65 and provides a private right of action for all protected classes for disparate treatment as well as disparate impacts. Some, including Elger and Spaulding (2010) , have argued that prisoners should enjoy the same access to biomedical research opportunities as nonprisoners. 66 International human rights law also lends support to the notion that prisoners not be unnecessarily restricted from precision medicine. The United Nations in its resolution on the treatment of prisoners stated clearly, 'Prisoners shall have access to the health services available in the country without discrimination on the grounds of their legal situation'. 67 As precision medicine becomes available in the USA, the reasonable interpretation is that this resolution would also indicate that precision medicine should not be denied to prisoners by simple virtue of their prison status.
This (viewed in light of the racial disparities in our criminal justice system, bolstered by an understanding of incarceration as a juridic disability, and recognition of the limits on prison regulations infringing on constitutional rights 68 ) opens the door to both criticism and liability for the exclusion of prisoners from biomedical research has symbolic significance for society. 72 In today's context of participant-centered research and healthcare, we ought to take another look so that we may learn from the past and shape the future. PMI's success will undoubtedly be affected by our willingness to do so.
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